Skip to main content
. 2020 Oct 27;10(4):1751–1761. doi: 10.3233/JPD-202058

Fig. 1.

Fig. 1

Study design. PD, Parkinson’s disease; SNRI, serotonin/norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.